237 related articles for article (PubMed ID: 35261888)
1. A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma.
Yan L; Lin J; Ke K; Wu Z; Huang J; Huang N; Yang W
Transl Cancer Res; 2022 Jan; 11(1):99-112. PubMed ID: 35261888
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Zhuang BW; Li W; Xie XH; Hu HT; Lu MD; Xie XY
Jpn J Clin Oncol; 2019 Sep; 49(9):845-855. PubMed ID: 31063184
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Long Y; Song X; Guan Y; Lan R; Huang Z; Li S; Zhang L
J Gastroenterol Hepatol; 2023 Apr; 38(4):486-495. PubMed ID: 36516040
[TBL] [Abstract][Full Text] [Related]
4. Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Kong S; Yu H; Wang H; Song J; Yan J
Clin J Gastroenterol; 2023 Dec; 16(6):793-802. PubMed ID: 37740882
[TBL] [Abstract][Full Text] [Related]
5. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
Liu M; Shi J; Mou T; Wang Y; Wu Z; Shen A
J Gastroenterol Hepatol; 2020 Aug; 35(8):1277-1287. PubMed ID: 32052876
[TBL] [Abstract][Full Text] [Related]
6. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma.
Liu BJ; Gao S; Zhu X; Guo JH; Zhang X; Chen H; Wang XD; Yang RJ
World J Gastrointest Oncol; 2020 Jun; 12(6):663-676. PubMed ID: 32699581
[TBL] [Abstract][Full Text] [Related]
8. Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: A meta-analysis.
Long GB; Xiao CW; Zhao XY; Zhang J; Li X
Medicine (Baltimore); 2020 Jun; 99(26):e20745. PubMed ID: 32590750
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
Jeong SW; Jang JY; Lee JE; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim YJ
Asia Pac J Clin Oncol; 2012 Jun; 8(2):164-71. PubMed ID: 22524575
[TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Peng P; Wen B; Chen R; Deng X
Turk J Gastroenterol; 2023 Apr; 34(4):311-321. PubMed ID: 37089046
[TBL] [Abstract][Full Text] [Related]
12. Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Kim HJ; Lee SH; Shim HJ; Bang HJ; Cho SH; Chung IJ; Hwang EC; Hwang JE; Bae WK
Front Oncol; 2023; 13():1265240. PubMed ID: 37881486
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study.
Hiramine Y; Uto H; Imamura Y; Tabu K; Baba Y; Hiwaki T; Sho Y; Tahara K; Higashi H; Tamai T; Oketani M; Ido A; Tsubouchi H
Exp Ther Med; 2011 May; 2(3):433-441. PubMed ID: 22977522
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Ueshima K; Ogasawara S; Ikeda M; Yasui Y; Terashima T; Yamashita T; Obi S; Sato S; Aikata H; Ohmura T; Kuroda H; Ohki T; Nagashima K; Ooka Y; Takita M; Kurosaki M; Chayama K; Kaneko S; Izumi N; Kato N; Kudo M; Omata M
Liver Cancer; 2020 Sep; 9(5):583-595. PubMed ID: 33083282
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Ouyang G; Pan G; Xu H; Wu Y; Liu Z; Lu W; Yi B; Chen X
J Clin Gastroenterol; 2020 Sep; 54(8):675-681. PubMed ID: 32569032
[TBL] [Abstract][Full Text] [Related]
16. Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review.
Zhang W; Ouyang D; Huang Z; Che X
Front Oncol; 2023; 13():1085166. PubMed ID: 36776344
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Hepatic Arterial Infusion Chemotherapy and Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Liu H; Qin X; Jiang H; Sun C; Wu M; Xu Z; Lu T; Ma X; Han Z
J Gastrointestin Liver Dis; 2022 Sep; 31(3):336-343. PubMed ID: 36112704
[TBL] [Abstract][Full Text] [Related]
18. Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis.
Dai Y; Jiang H; Jiang H; Zhao S; Zeng X; Sun R; Zheng R
Transl Oncol; 2021 Dec; 14(12):101238. PubMed ID: 34628285
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
[TBL] [Abstract][Full Text] [Related]
20. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Tan Z; Zhang J; Xu L; Wang H; Mao X; Zou R; Wang Q; Han Z; Di Z; Wu D
PLoS One; 2023; 18(10):e0290644. PubMed ID: 37844117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
